Pharmaceuticals, Biotechnology and Life Sciences
HALIX B.V. has signed an agreement with AstraZeneca AB for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.
SeraNovoa pharmaceutical company with a breakthrough proprietary formulation platform for enhancing drug bioavailability has appointed Dr Michiel Van Speybroeck to the role of Chief Development Officer (CDO) with immediate effect.
Osteolab has completed a second financing round in the amount of approximately €1.6 million. The funds were provided by Seed and Start-Up Fonds II of MBG (Mittelständische Beteiligungsgesellschaft) Kiel, Labor Dr. Krause & Kollegen MVZ GmbH, Kiel, and SVM Verwaltungsgesellschaft mbH, Hamburg, as new shareholders.
GeGant® for the U.S. market will be produced and distributed by ITM’s long-term partner RadioMedix GARCHING, Germany & HOUSTON–(BUSINESS WIRE)–ITM…
German independent research institute Biomed X announces has completed its first joint research project with Boehringer Ingelheim in the fields of neuroscience. The results of the project are transferred to Boehringer Ingelheim for further development.
Relief Therapeutics and NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
The UK has approved Pfizer’s COVID-19 vaccine on Wednesday, becoming the first country in the world to do so, going ahead of the United States and the EU countries, who expect to bring the decisions on authorization in December.
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.
The Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID), to test Marinomed Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections.
UK government has now secured 7 million doses of mRNA-1273 Agreement reflects Moderna’s commitment to make its vaccine available in…